Derived From Cannabis, Pt. 4 Cannabigerol (CBG)

January 29, 2013

The fourth cannaboid that our government is keeping from us is called Cannabigerol or (CBG). It is non-psychoactive. Cannabigerol is found in higher concentrations in hemp rather than in varieties of Cannabis cultivated for high THC content and their corresponding psychoactive properties.

Cannabigerol has been found to act as a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist. It also binds to the CB2 receptor, but whether it acts as an agonist or antagonist at this site is unknown.

Cannabigerol has been shown to relieve intraoccular pressure, which may be of benefit in the treatment of glaucoma. Similar to CBC, cannabigerol (CBG) also has been subject to relatively few scientific trials since its discovery in 1964. To date, there exist only limited number of papers available referencing the substance – a keyword search on PubMed yields fewer than 55 citations – which has been documented to possess anti-cancer, anti-inflammatory, analgesic, and anti-bacterial properties.  

According to a 2011 review published in the British Journal of Pharmacology, “[A] whole plant extract of a CBG-chemotype…would seem to offer an excellent, safe new antiseptic agent” for the treatment of multi-drug resistant bacteria. A more recent review published this year in the journal Pharmacology & Therapeutics further acknowledges that CBG and similar non-psychotropic cannabinoids “act at a wide range of pharmacological targets” and could potentially be utilized in the treatment of a wide range of central nervous system disorders, including epilepsy.

Do you know someone suffering from glaucoma or epilepsy?  How does it make you feel knowing there is alternatice medicine that could be used to treat these conditions, along with who knows what else if our government would end prohibition of cannabis?